Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 9/20 | 0.65 |
| ▸ | MAOA | P21397 | 2/20 | 0.65 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.65 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.60 |
| ▸ | GRM5 | P41594 | 1/20 | 0.55 |
| ▸ | PPARA | Q07869 | 1/20 | 0.55 |
| ▸ | NR4A2 | P43354 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3976085 | 0.89 | MAOB (0.58) | MAOBMAOASCN9APARP10GRM5 | |
| SCHEMBL3971368 | 0.87 | MAOB (0.58) | MAOBMAOASCN9APARP10GRM5 | |
| SCHEMBL3064569 | 0.87 | MAOB (0.58) | MAOBMAOASCN9APARP10PPARA | |
| SCHEMBL3969644 | 0.86 | MAOB (0.57) | MAOBMAOA | |
| SCHEMBL3967573 | 0.86 | PARP15 (0.60) | MAOBMAOASCN9APARP10 | |
| SCHEMBL3970941 | 0.81 | FFAR1 (0.57) | MAOBMAOASCN9APPARA | |
| SCHEMBL8935241 | 0.81 | MAOB (0.63) | MAOBMAOASCN9APARP10GRM5 | |
| SCHEMBL5684175 | 0.80 | MAOB (0.56) | MAOBMAOASCN9APARP10GRM5 | |
| SCHEMBL920177 | 0.80 | SCN3A (0.65) | MAOBSCN9APARP10 | |
| SCHEMBL963386 | 0.80 | SPHK2 (0.67) | MAOBMAOASCN9APARP10PPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 89 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2977046-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | Newron Pharmaceuticals S.p.A. (IT) | 2016-01-27 | — | — | EP | claimed |
| US-8697738-B2 | Alpha-aminoamide derivatives useful in the treatment of addictive disorders | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2014-04-15 | — | — | US | claimed |
| US-20130217747-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME | NEWRON PHARM SPA (US) | 2013-08-22 | — | — | US | claimed |
| CN-102274517-A | Methods for treatment of parkinson's disease | — | 2011-12-14 | — | — | CN | claimed |
| EP-2343064-A1 | Alpha-aminoamide derivatives useful in the treatment of cognitive disorders | Newron Pharmaceuticals S.p.A. (IT) | 2011-07-13 | — | — | EP | claimed |
| EP-1900362-B1 | Alfa-aminoamide derivatives useful in the treatment of addictive disorders | NEWRON PHARM SPA (IT) | 2011-01-12 | — | — | EP | claimed |
| EP-1658062-B1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | NEWRON PHARM SPA (IT) | 2010-02-17 | — | — | EP | claimed |
| US-20100016437-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-01-21 | — | — | US | claimed |
| US-20100016440-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2010-01-21 | — | — | US | claimed |
| EP-2070526-A1 | \"Methods for treatment of Parkinson's disease\ | Newron Pharmaceuticals S.p.A. (IT) | 2009-06-17 | — | — | EP | claimed |
| WO-2005018627-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | NEWRON PHARMACEUTICALS, SPA (IT) | 2005-03-03 | — | — | WO | claimed |
| WO-2004089353-A2 | METHODS FOR TREATMENT OF PARKINSON'S DISEASE | NEWRON PHARMACEUTICALS, S.P.A. (IT) | 2004-10-21 | — | — | WO | claimed |
| EP-1045830-B1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANALGESIC AGENTS | NEWRON PHARM SPA (IT) | 2003-04-23 | — | — | EP | claimed |
| US-6306903-B1 | ANALGESICS FOR ALLEVIATION OF CHRONIC AND NEUROPATHIC PAIN. | NEWRON PHARMACEUTICALS S.P.A. (IT) | 2001-10-23 | — | — | US | claimed |
| EP-0842143-B1 | 2-(4-SUBSTITUTED)-BENZYLAMINO-2-METHYL-PROPANAMIDE DERIVATIVES | NEWRON PHARM SPA (IT) | 2001-06-13 | — | — | EP | claimed |
| EP-1045830-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANALGESIC AGENTS | Newron Pharmaceuticals S.p.A. (IT) | 2000-10-25 | — | — | EP | claimed |
| US-5945454-A | 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives | PHARMACIA & UPJOHN, S.P.A. (IT) | 1999-08-31 | — | — | US | claimed |
| WO-1999035125-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANALGESIC AGENTS | NEWRON PHARMACEUTICALS S.P.A. (IT) | 1999-07-15 | — | — | WO | claimed |
| EP-0842143-A1 | 2-(4-SUBSTITUTED)-BENZYLAMINO-2-METHYL-PROPANAMIDE DERIVATIVES | PHARMACIA & UPJOHN S.p.A. (IT) | 1998-05-20 | — | — | EP | claimed |
| WO-1997005102-A1 | 2-(4-SUBSTITUTED)-BENZYLAMINO-2-METHYL-PROPANAMIDE DERIVATIVES | PHARMACIA & UPJOHN S.P.A. (IT) | 1997-02-13 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100016437-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF COGNITIVE DISORDERS | PSEN1, MAPT, AADAT | MAOB 709/4885MAOA 506/4885SCN9A 3223/4885 |
| US-20100016440-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL AS ANTI-INFLAMMATORY AGENTS | IL1A, AADAT, DNPEP | MAOB 1206/4885MAOA 525/4885SCN9A 2253/4885 |
| US-20130217747-A1 | ALPHA-AMINOAMIDE DERIVATIVES USEFUL IN THE TREATMENT OF RESTLESS LEGS SYNDROME | AADAT, PNMT, BCAT2 | MAOB 53/4885MAOA 58/4885SCN9A 946/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.